Core Viewpoint - Aimeson has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors being CCB International and Bank of Communications International [1] Company Summary - Aimeson is a leading early cancer detection company focused on high incidence and high mortality cancers, having developed a methylation-based early cancer detection technology [1] - The company's core products include Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer, with Aixin Gan being the world's first liver cancer detection reagent based on methylation and qPCR technology, achieving a sensitivity of 84.43% for stage I liver cancer [1] - Aiguang Le allows for non-invasive detection of urinary tract cancer using just 1 milliliter of urine, enhancing efficiency and convenience [1] - Aimeson has a comprehensive early cancer detection platform covering multiple cancers, including colorectal, liver, esophageal, urinary tract, gastric, lung, and gynecological cancers, and is developing several combination detection reagents [1] Industry Summary - The Chinese tumor molecular testing market is rapidly growing, with an expected market size of 38.8 billion RMB by 2033 [1] - Aimeson employs cost-effective qPCR technology combined with proprietary iTBFinder platform, AS-Cap technology, and SEM-PCR technology to enhance detection capabilities [1] - The company is developing an automated sample processing workstation, AMStation, to support large-scale testing [1]

智通财经APP获悉，据港交所9月28日披露，武汉艾米森生命科技股份有限公司(简称：艾米森)向港交所主板提交上市申请书，联席保荐人为建银国 际、交银国际。 招股书显示，艾米森是一家领先的早期癌症检测公司，战略聚焦于高发病率、高死亡率的癌症。公司率先开发基于甲基化的早期癌症检测技术。公司 拥有两款核心产品，分别为针对肝癌的艾馨甘及针对尿路上皮癌的艾光乐。艾馨甘是全球首款基于甲基化技术、采用即时定量聚合酶链反应 （"qPCR"）技术的肝癌检测试剂，通过血液样本检测肝癌的灵敏度达92.33%，特异性达93.35%，对I期患者的灵敏度更高达84.43%。公司的另一款核 心产品艾光乐仅需用1毫升尿液样本即可实现尿路上皮癌的非侵入性检测，与传统方法相比，显著提升效率及便利性。 公司深耕中国高速增长的肿瘤分子检测市场。根据弗若斯特沙利文的资料，于2024年，中国肝癌的发病率居第四位，癌症相关死亡率居第二位，而尿 路上皮癌则具有高复发的特点。该等癌症的早筛可以显著提高生存率，同时降低晚期治疗相关的医疗成本。尽管中国的肿瘤分子检测仍处于早期阶 段，渗透率较低，但根据弗若斯特沙利文的资料，该领域正在快速发展。根据弗若斯特沙利文的资 ...

Core Viewpoint - Mirxes-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the FDA in the US [1] - GASTROClear has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - Guoyuan International believes that the company has significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as one of the global leaders in this sector [1] - Everbright Securities International previously noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share (66.3%) in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and other disease screening [1] - The flagship product, GASTROClear™/觅小卫™, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the US FDA [1] - GASTROClear™ has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - According to Guoyuan International, the company holds significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as a global leader [1] - Everbright Securities International noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening globally, holding the largest market share of 66.3% in the Southeast Asian miRNA liquid biopsy gastric cancer screening market as of 2023 [1]